Article Menu
Need Help?
Article Versions Notes
Action | Date | Notes | Link |
---|---|---|---|
article pdf uploaded. | 27 September 2024 18:34 CEST | Version of Record | https://www.mdpi.com/2072-6694/16/19/3317/pdf |
Cite
Houvenaeghel, G.; Classe, J.-M.; Chauvet, M.-P.; Colombo, P.-E.; Jouve, E.; Reyal, F.; Daraï, E.; Rouzier, R.; Faure-Virelizier, C.; Gimbergues, P.; et al. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. Cancers 2024, 16, 3317. https://doi.org/10.3390/cancers16193317
Houvenaeghel G, Classe J-M, Chauvet M-P, Colombo P-E, Jouve E, Reyal F, Daraï E, Rouzier R, Faure-Virelizier C, Gimbergues P, et al. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. Cancers. 2024; 16(19):3317. https://doi.org/10.3390/cancers16193317
Chicago/Turabian StyleHouvenaeghel, Gilles, Jean-Marc Classe, Marie-Pierre Chauvet, Pierre-Emmanuel Colombo, Eva Jouve, Fabien Reyal, Emile Daraï, Roman Rouzier, Christelle Faure-Virelizier, Pierre Gimbergues, and et al. 2024. "Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery" Cancers 16, no. 19: 3317. https://doi.org/10.3390/cancers16193317